Clinical Trial

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Study acronym: PRISM
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-12-11; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-12-17
Trial Details
NCT Number NCT07285213
Lead Sponsor AstraZeneca
Conditions Clostridioides Difficile Infection
Enrollment 230 participants
Start Date 2025-12-10
Primary Completion 2027-04-20 (estimated)
Study Completion 2028-01-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-12